ImmuCell Corporation (FRA:IUL)

ImmuCell Statistics

Total Valuation

ImmuCell has a market cap or net worth of EUR 36.88 million. The enterprise value is 45.24 million.

Market Cap	36.88M
Enterprise Value	45.24M

Important Dates

The next estimated earnings date is Wednesday, February 25, 2026.

Earnings Date	Feb 25, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	9.05M
Shares Outstanding	n/a
Shares Change (YoY)	+14.38%
Shares Change (QoQ)	+0.16%
Owned by Insiders (%)	27.96%
Owned by Institutions (%)	18.01%
Float	6.01M

Valuation Ratios

The trailing PE ratio is 18.62.

PE Ratio	18.62
Forward PE	n/a
PS Ratio	1.56
PB Ratio	1.45
P/TBV Ratio	1.46
P/FCF Ratio	60.49
P/OCF Ratio	21.75
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.86, with an EV/FCF ratio of 74.21.

EV / Earnings	22.85
EV / Sales	1.89
EV / EBITDA	8.86
EV / EBIT	19.23
EV / FCF	74.21

Financial Position

The company has a current ratio of 4.21, with a Debt / Equity ratio of 0.46.

Current Ratio	4.21
Quick Ratio	1.62
Debt / Equity	0.46
Debt / EBITDA	2.29
Debt / FCF	19.02
Interest Coverage	5.23

Financial Efficiency

Return on equity (ROE) is 8.27% and return on invested capital (ROIC) is 4.01%.

Return on Equity (ROE)	8.27%
Return on Assets (ROA)	3.79%
Return on Invested Capital (ROIC)	4.01%
Return on Capital Employed (ROCE)	6.56%
Revenue Per Employee	292,195
Profits Per Employee	24,450
Employee Count	75
Asset Turnover	0.62
Inventory Turnover	1.85

Taxes

In the past 12 months, ImmuCell has paid 12,188 in taxes.

Income Tax	12,188
Effective Tax Rate	0.61%

Stock Price Statistics

The stock price has increased by +16.67% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+16.67%
50-Day Moving Average	5.08
200-Day Moving Average	5.09
Relative Strength Index (RSI)	32.32
Average Volume (20 Days)	37

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	0.31

Income Statement

In the last 12 months, ImmuCell had revenue of EUR 23.67 million and earned 1.98 million in profits. Earnings per share was 0.22.

Revenue	23.67M
Gross Profit	10.03M
Operating Income	2.33M
Pretax Income	1.99M
Net Income	1.98M
EBITDA	4.63M
EBIT	2.33M
Earnings Per Share (EPS)	0.22

Balance Sheet

The company has 3.31 million in cash and 11.60 million in debt, giving a net cash position of -8.28 million.

Cash & Cash Equivalents	3.31M
Total Debt	11.60M
Net Cash	-8.28M
Net Cash Per Share	n/a
Equity (Book Value)	25.40M
Book Value Per Share	2.81
Working Capital	10.93M

Cash Flow

In the last 12 months, operating cash flow was 1.70 million and capital expenditures -1.09 million, giving a free cash flow of 609,693.

Operating Cash Flow	1.70M
Capital Expenditures	-1.09M
Free Cash Flow	609,693
FCF Per Share	n/a

Margins

Gross margin is 42.40%, with operating and profit margins of 9.85% and 8.37%.

Gross Margin	42.40%
Operating Margin	9.85%
Pretax Margin	8.42%
Profit Margin	8.37%
EBITDA Margin	19.56%
EBIT Margin	9.85%
FCF Margin	2.58%

Dividends & Yields

ImmuCell does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-14.38%
Shareholder Yield	-14.38%
Earnings Yield	5.37%
FCF Yield	1.65%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ImmuCell has an Altman Z-Score of 2.54 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.54
Piotroski F-Score	7